Cantargia

3,81 SEK

+5,25 %

1.290 følger denne virksomhed

CANTA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+5,25 %

+51,49 %

+27,85 %

+129,52 %

+125,44 %

+95,89 %

+5,60 %

-92,36 %

-46,09 %

Cantargia operates in the pharmaceutical industry and focuses on the development of treatments for cancer and inflammatory diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Cantargia was founded in 2009 and is headquartered in Lund, Sweden.

Markedsværdi

947,21 mio. SEK

Aktieomsætning

13,01 mio. SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

19.11

2025

Delårsrapport Q3'25

20.2

2026

Årsrapport '25

Alle

Selskabspræsentationer

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Selskabsmeddelelsefor 11 timer siden

Cantargia presents Nomination Committee ahead of 2026 AGM

Cantargia, Audiocast, Q3'25

Videopræsentation19.11.2025, 14.00

Cantargia, Audiocast, Q3'25

Pressemeddelelse5.11.2025, 08.30

Invitation to the Presentation of Cantargia’s Interim Report January-September 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse23.10.2025, 11.30

Cantargia to Participate in Upcoming Conferences

Pressemeddelelse7.10.2025, 11.27

BioStock: Cantargia:”Our data is very compelling”

Selskabsmeddelelse2.10.2025, 05.30

Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer

Pressemeddelelse30.9.2025, 22.00

Cantargia presents data at an AACR Conference strengthening IL1RAP as a targetable hallmark in PDAC

Pressemeddelelse25.9.2025, 09.32

BioStock: Video from Cantargias presentation at BioStock Investing in Life Science – From Seed to Success

Selskabsmeddelelse11.9.2025, 05.30

Cantargia closes the acquisition of CAN10 by Otsuka

Pressemeddelelse27.8.2025, 05.30

Cantargia granted important US patent for nadunolimab

Pressemeddelelse25.8.2025, 09.25

Redeye: Cantargia Q2 2025 - Major Deal and Negative TRIFOUR Readout

Cantargia, Audiocast, Q2'25

Videopræsentation21.8.2025, 13.00

Cantargia, Audiocast, Q2'25

Selskabsmeddelelse21.8.2025, 05.00

Cantargia publishes half-year report 2025

Selskabsmeddelelse18.8.2025, 16.25

Cantargia appoints Dr Hilde Steineger as Chief Executive Officer

Pressemeddelelse12.8.2025, 08.15

Invitation to the presentation of Cantargia’s H1 2025 report

Selskabsmeddelelse17.7.2025, 19.30

Cantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC)

Pressemeddelelse17.7.2025, 10.25

BioStock: Otsuka Pharmaceutical acquires Cantargia’s CAN10 program in a deal worth over USD 600 million

Pressemeddelelse16.7.2025, 12.15

Cantargia announces publication of clinical data showing benefit of nadunolimab combination therapy in advanced lung cancer

Selskabsmeddelelse15.7.2025, 06.45

Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by Otsuka Pharmaceutical

Selskabsmeddelelse17.6.2025, 17.45

Cantargia signs SEK 50 million financing facility agreement, extending cash runway into 2026 and providing operating flexibility to drive strategic plans

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.